Kobayashi Pharmaceutical, a Japanese drugmaker, is facing challenges in restoring public trust after failing to promptly disclose potential health hazards due to economic considerations, according to a local medical professional. The Osaka-based pharmaceutical giant has initiated recalls of several products. As of Friday, the products have been associated with five deaths and over 100 hospitalizations, with nearly 700 others seeking medical advice or planning to do so.